Vaginal Atrophy in Postmenopausal Women. Postmenopausal atrophic vaginitis
Conditions
Interventions
Intervention 1: First intervention group: Vaginal Cream, Conjugated Estrogen ./625 Mg, one mg for 12 weeks (the first two weeks, each night and the next 10 weeks, two nights a week), Aburaihan Pharmac
Treatment - Drugs
Placebo
First intervention group: Vaginal Cream, Conjugated Estrogen ./625 Mg, one mg for 12 weeks (the first two weeks, each night and the next 10 weeks, two nights a week), Aburaihan Pharmacy Company
Two intervention group:chamomile vaginal gel 5%, one mg for 12 weeks (the first two weeks, each night and the next 10 weeks, two nights a week)
Control group: placebo vaginal gel, one mg for 12 weeks (the first two weeks, each night and the next 10 weeks, two nights a week)
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: People who have had at least one year of their last menstruation or have a hormonal test with an average fsh> 40 international units There are symptoms of vaginal atrophy The age range is 45-65 years Have sex and monogamy
Exclusion criteria
Exclusion criteria: Vaginal infection needs treatment Genital abnormalities Hormone therapy or use of sexual hormones during the 8 weeks prior to the study Using vaginal medicines or any lubricant at least 15 days before the study Tobacco use (alcohol, cigarette and hookah) Breast diseases with unknown cause Uterine bleeding or spotting with unspecified cause Excessive consumption of phytoestrogens such as soy, red clover, fenugreek over the past month BMI more than 30 Cholestatic Diseases of the Liver Severe kidney failure Acute Thrombophlebitis High blood pressure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal atrophy. Timepoint: At the beginning of the study, 14, 42 and 84 days after Intervention. Method of measurement: Cooperman Index Questionnaire.;Percentage of vaginal cell maturation. Timepoint: Before intervention, after intervention. Method of measurement: Vaginal smear.;Vaginal acidity. Timepoint: Before intervention, after intervention. Method of measurement: PH gauge. | — |
Secondary
| Measure | Time frame |
|---|---|
| Painful intercourse. Timepoint: At the beginning of the study, 14, 42 and 84 days after Intervention. Method of measurement: Self-assessment scale is 4 degrees.;Menopause symptoms. Timepoint: At the beginning of the study, 14, 42 and 84 days after Intervention. Method of measurement: Cooperman Index Questionnaire.;Severity of menopause symptoms. Timepoint: At the beginning of the study, 14, 42 and 84 days after Intervention. Method of measurement: Menopause Rating Scale.;Sexual performance. Timepoint: Before and after the intervention. Method of measurement: Female Sexual Function Index (FSFI).;Sexual satisfaction. Timepoint: Before and after the intervention. Method of measurement: Larson Sexual Satisfaction Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Bosak
Ahvaz University of Medical Sciences
Outcome results
None listed